Safety and Preliminary Efficacy of VG801 in Patients With ABCA4 Mutation-associated Retinal Dystrophy (Stargardt Disease)

NCT07002398 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

15

Enrollment

INDUSTRY

Sponsor class

Conditions

Retinal Dystrophy Due to Biallelic ABCA4 Mutations
Stargardt Disease 1

Interventions

DRUG: VG801

Sponsor

VeonGen Therapeutics GmbH